Department of Communication Sciences & Disorders, University of Haifa, Mt. Carmel, Haifa, Israel.
Eur Arch Otorhinolaryngol. 2012 Feb;269(2):461-6. doi: 10.1007/s00405-011-1668-x. Epub 2011 Jul 8.
The aim of this prospective clinical study was to test auditory function in patients with Laron syndrome, either untreated or treated with insulin-like growth factor I (IGF-I). The study group consisted of 11 patients with Laron syndrome: 5 untreated adults, 5 children and young adults treated with replacement IGF-I starting at bone age <2 years, and 1 adolescent who started replacement therapy at bone age 4.6 years. The auditory evaluation included pure tone and speech audiometry, tympanometry and acoustic reflexes, otoacoustic emissions, loudness dynamics, auditory brain stem responses and a hyperacusis questionnaire. All untreated patients and the patient who started treatment late had various degrees of sensorineural hearing loss and auditory hypersensitivity; acoustic middle ear reflexes were absent in most of them. All treated children had normal hearing and no auditory hypersensitivity; most had recordable middle ear acoustic reflexes. In conclusion, auditory defects seem to be associated with Laron syndrome and may be prevented by starting treatment with IGF-I at an early developmental age.
本前瞻性临床研究旨在测试 Laron 综合征患者的听觉功能,包括未经治疗和接受胰岛素样生长因子 I(IGF-I)治疗的患者。研究组包括 11 名 Laron 综合征患者:5 名未治疗的成年人、5 名儿童和青少年,他们在骨龄<2 岁时开始接受 IGF-I 替代治疗,以及 1 名在骨龄 4.6 岁时开始接受替代治疗的青少年。听觉评估包括纯音和言语测听、鼓室图和声反射、耳声发射、响度动态、听觉脑干反应和听觉过敏问卷。所有未经治疗的患者和治疗开始较晚的患者都有不同程度的感音神经性听力损失和听觉过敏;他们中的大多数人中耳声反射都缺失。所有接受治疗的儿童都有正常的听力,没有听觉过敏;大多数人可记录到中耳声反射。总之,听觉缺陷似乎与 Laron 综合征有关,通过在早期发育阶段开始 IGF-I 治疗可能预防这些缺陷。